Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.43 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | DUSP10 | Q9Y6W6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2304288 | 1.00 | MEN1 (0.50) | MEN1RAB9AKMT2ACNR2CNR1 | |
| SCHEMBL818155 | 0.87 | CCR1 (0.38) | CNR2CNR1SCN9AIRAK4 | |
| SCHEMBL13400154 | 0.87 | CCR1 (0.38) | CNR2CNR1SCN9AIRAK4 | |
| SCHEMBL6650361 | 0.87 | ALDH1A1 (0.56) | MEN1KMT2ASCN9AALDH1A1POLB | |
| SCHEMBL6673866 | 0.82 | ALDH1A1 (0.44) | MEN1RAB9AKMT2ACNR2CNR1 | |
| SCHEMBL12137374 | 0.80 | MEN1 (0.56) | MEN1RAB9AKMT2ACNR2ASIC3 | |
| SCHEMBL5109868 | 0.80 | MEN1 (0.60) | MEN1RAB9AKMT2AASIC3TRPV3 | |
| SCHEMBL6648617 | 0.78 | SCN9A (0.47) | SCN9A | |
| SCHEMBL2609332 | 0.76 | KMT2A (0.60) | MEN1RAB9AKMT2ACNR2CNR1 | |
| SCHEMBL22481106 | 0.75 | ADRB1 (0.60) | MEN1RAB9AKMT2ATRPV3SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586498-B2 | Homogeneous asymmetric hydrogenation catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-11-19 | — | — | US | disclosed |
| US-8586498-B2 | Homogeneous asymmetric hydrogenation catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-11-19 | — | — | US | disclosed |
| US-8497400-B2 | Homogeneous asymmetric hydrogenation process | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-07-30 | — | — | US | disclosed |
| US-8497400-B2 | Homogeneous asymmetric hydrogenation process | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-07-30 | — | — | US | disclosed |
| US-8481791-B2 | Homogeneous asymmetric hydrogenation process | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-07-09 | — | — | US | disclosed |
| US-8481791-B2 | Homogeneous asymmetric hydrogenation process | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-07-09 | — | — | US | disclosed |
| US-20110065929-A1 | HOMOGENEOUS ASYMMETRIC HYDROGENATION CATALYST | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-03-17 | — | — | US | disclosed |
| US-20110065929-A1 | HOMOGENEOUS ASYMMETRIC HYDROGENATION CATALYST | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-03-17 | — | — | US | disclosed |
| US-7902110-B2 | Homogeneous asymmetric hydrogenation catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-03-08 | — | — | US | disclosed |
| US-7902110-B2 | Homogeneous asymmetric hydrogenation catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20100168440-A1 | Homogeneous Asymmetric Hydrogenation Process | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168440-A1 | Homogeneous Asymmetric Hydrogenation Process | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100137615-A1 | Homogeneous Asymmetric Hydrogenation Process | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100137615-A1 | Homogeneous Asymmetric Hydrogenation Process | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-06-03 | — | — | US | disclosed |
| EP-2095875-A1 | Homogeneous asymmetric hydrogenation catalyst | Takasago International Corporation (JP) | 2009-09-02 | — | — | EP | disclosed |
| US-20090203927-A1 | Homogeneous asymmetric hydrogenation catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-08-13 | — | — | US | disclosed |
| US-20090203927-A1 | Homogeneous asymmetric hydrogenation catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-1911516-A1 | HOMOGENEOUS ASYMMETRIC HYDROGENATION CATALYST | Takasago International Corporation (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137615-A1 | Homogeneous Asymmetric Hydrogenation Process | HDHD5, HHAT, HVCN1 | MEN1 3092/4885RAB9A 2082/4885KMT2A 1200/4885 |
| US-20090203927-A1 | Homogeneous asymmetric hydrogenation catalyst | HDHD5, HHAT, HACL2 | MEN1 2776/4885RAB9A 2049/4885KMT2A 847/4885 |
| US-20110065929-A1 | HOMOGENEOUS ASYMMETRIC HYDROGENATION CATALYST | HDHD5, HHAT, HACL2 | MEN1 2776/4885RAB9A 2049/4885KMT2A 847/4885 |
| US-20100168440-A1 | Homogeneous Asymmetric Hydrogenation Process | HDHD5, HHAT, HVCN1 | MEN1 3092/4885RAB9A 2082/4885KMT2A 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.